Efficacy	efficacy	O	O
and	and	O	O
tolerability	tolerability	O	O
of	of	O	O
lovastatin	lovastatin	S_chemical	O
in	in	O	O
3390	3390	O	O
women	women	O	O
with	with	O	O
moderate	moderate	O	O
hypercholesterolemia	hypercholesterolemia	O	S_disease
.	.	O	O

OBJECTIVE	objective	O	O
:	:	O	O
To	to	O	O
evaluate	evaluate	O	O
the	the	O	O
efficacy	efficacy	O	O
and	and	O	O
safety	safety	O	O
of	of	O	O
lovastatin	lovastatin	S_chemical	O
in	in	O	O
women	women	O	O
with	with	O	O
moderate	moderate	O	O
hypercholesterolemia	hypercholesterolemia	O	S_disease
.	.	O	O

DESIGN	design	O	O
:	:	O	O
The	the	O	O
Expanded	expanded	O	O
Clinical	clinical	O	O
Evaluation	evaluation	O	O
of	of	O	O
Lovastatin	lovastatin	S_chemical	O
(	(	O	O
EXCEL	excel	O	O
)	)	O	O
Study	study	O	O
,	,	O	O
a	a	O	O
multicenter	multicenter	O	O
,	,	O	O
double-blind	double-blind	O	O
,	,	O	O
diet-	diet-	O	O
and	and	O	O
placebo-controlled	placebo-controlled	O	O
trial	trial	O	O
,	,	O	O
in	in	O	O
which	which	O	O
participants	participants	O	O
were	were	O	O
randomly	randomly	O	O
assigned	assigned	O	O
to	to	O	O
receive	receive	O	O
placebo	placebo	O	O
or	or	O	O
lovastatin	lovastatin	S_chemical	O
at	at	O	O
doses	doses	O	O
of	of	O	O
20	20	O	O
or	or	O	O
40	40	O	O
mg	mg	O	O
once	once	O	O
daily	daily	O	O
,	,	O	O
or	or	O	O
20	20	O	O
or	or	O	O
40	40	O	O
mg	mg	O	O
twice	twice	O	O
daily	daily	O	O
for	for	O	O
48	48	O	O
weeks	weeks	O	O
.	.	O	O

SETTING	setting	O	O
:	:	O	O
Ambulatory	ambulatory	O	O
patients	patients	O	O
recruited	recruited	O	O
by	by	O	O
362	362	O	O
participating	participating	O	O
centers	centers	O	O
throughout	throughout	O	O
the	the	O	O
United	united	O	O
States	states	O	O
.	.	O	O

PATIENTS	patients	O	O
:	:	O	O
Women	women	O	O
(	(	O	O
n	n	O	O
=	=	O	O
3390	3390	O	O
)	)	O	O
from	from	O	O
the	the	O	O
total	total	O	O
cohort	cohort	O	O
of	of	O	O
8245	8245	O	O
volunteers	volunteers	O	O
.	.	O	O

MEASUREMENTS	measurements	O	O
:	:	O	O
Plasma	plasma	O	O
total	total	O	O
,	,	O	O
low-density	low-density	O	O
lipoprotein	lipoprotein	O	O
(	(	O	O
LDL	ldl	O	O
)	)	O	O
,	,	O	O
and	and	O	O
high-density	high-density	O	O
lipoprotein	lipoprotein	O	O
(	(	O	O
HDL	hdl	O	O
)	)	O	O
cholesterol	cholesterol	S_chemical	O
,	,	O	O
and	and	O	O
triglycerides	triglycerides	O	O
;	;	O	O
and	and	O	O
laboratory	laboratory	O	O
and	and	O	O
clinical	clinical	O	O
evidence	evidence	O	O
of	of	O	O
adverse	adverse	O	B_disease
events	events	O	I_disease
monitored	monitored	O	O
periodically	periodically	O	O
throughout	throughout	O	O
the	the	O	O
study	study	O	O
.	.	O	O

RESULTS	results	O	O
:	:	O	O
Among	among	O	O
women	women	O	O
,	,	O	O
lovastatin	lovastatin	S_chemical	O
(	(	O	O
20	20	O	O
to	to	O	O
80	80	O	O
mg/d	mg/d	O	O
)	)	O	O
produced	produced	O	O
sustained	sustained	O	O
(	(	O	O
12-	12-	O	O
to	to	O	O
48-week	48-week	O	O
)	)	O	O
,	,	O	O
dose-related	dose-related	O	O
changes	changes	O	O
(	(	O	O
P	p	O	O
<	<	O	O
0.001	0.001	O	O
):	):	O	O
decreases	decreases	O	O
in	in	O	O
LDL	ldl	O	O
cholesterol	cholesterol	S_chemical	O
(	(	O	O
24	24	O	O
%	%	O	O
to	to	O	O
40	40	O	O
%	%	O	O
)	)	O	O
and	and	O	O
triglycerides	triglycerides	O	O
(	(	O	O
9	9	O	O
%	%	O	O
to	to	O	O
18	18	O	O
%	%	O	O
)	)	O	O
,	,	O	O
and	and	O	O
increases	increases	O	O
in	in	O	O
HDL	hdl	O	O
cholesterol	cholesterol	S_chemical	O
(	(	O	O
6.7	6.7	O	O
%	%	O	O
to	to	O	O
8.6	8.6	O	O
%	%	O	O
)	)	O	O
.	.	O	O

Depending	depending	O	O
on	on	O	O
the	the	O	O
dose	dose	O	O
,	,	O	O
from	from	O	O
82	82	O	O
%	%	O	O
to	to	O	O
95	95	O	O
%	%	O	O
of	of	O	O
lovastatin-treated	lovastatin-treated	O	O
women	women	O	O
achieved	achieved	O	O
the	the	O	O
National	national	O	O
Cholesterol	cholesterol	S_chemical	O
Education	education	O	O
Program	program	O	O
goal	goal	O	O
of	of	O	O
LDL	ldl	O	O
cholesterol	cholesterol	S_chemical	O
levels	levels	O	O
less	less	O	O
than	than	O	O
4.14	4.14	O	O
mmol/L	mmol/l	O	O
(	(	O	O
160	160	O	O
mg/dL	mg/dl	O	O
)	)	O	O
,	,	O	O
and	and	O	O
40	40	O	O
%	%	O	O
to	to	O	O
87	87	O	O
%	%	O	O
achieved	achieved	O	O
the	the	O	O
goal	goal	O	O
of	of	O	O
3.36	3.36	O	O
mmol/L	mmol/l	O	O
(	(	O	O
130	130	O	O
mg/dL	mg/dl	O	O
)	)	O	O
.	.	O	O

Successive	successive	O	O
transaminase	transaminase	O	O
elevations	elevations	O	O
greater	greater	O	O
than	than	O	O
three	three	O	O
times	times	O	O
the	the	O	O
upper	upper	O	O
limit	limit	O	O
of	of	O	O
normal	normal	O	O
occurred	occurred	O	O
in	in	O	O
0.1	0.1	O	O
%	%	O	O
of	of	O	O
women	women	O	O
and	and	O	O
were	were	O	O
dose	dose	O	O
dependent	dependent	O	O
above	above	O	O
the	the	O	O
20-mg	20-mg	O	O
dose	dose	O	O
.	.	O	O

Myopathy	myopathy	O	S_disease
,	,	O	O
defined	defined	O	O
as	as	O	O
muscle	muscle	O	B_disease
symptoms	symptoms	O	I_disease
with	with	O	O
creatine	creatine	B_chemical	O
kinase	kinase	I_chemical	O
elevations	elevations	O	O
greater	greater	O	O
than	than	O	O
10	10	O	O
times	times	O	O
the	the	O	O
upper	upper	O	O
limit	limit	O	O
of	of	O	O
normal	normal	O	O
,	,	O	O
was	was	O	O
rare	rare	O	O
and	and	O	O
associated	associated	O	B_disease
with	with	O	I_disease
the	the	O	O
highest	highest	O	O
recommended	recommended	O	O
daily	daily	O	O
dose	dose	O	O
of	of	O	O
lovastatin	lovastatin	S_chemical	O
(	(	O	O
80	80	O	O
mg	mg	O	O
)	)	O	O
.	.	O	O

Estrogen-replacement	estrogen-replacement	O	O
therapy	therapy	O	O
appeared	appeared	O	O
to	to	O	O
have	have	O	O
no	no	O	O
effect	effect	O	O
on	on	O	O
either	either	O	O
the	the	O	O
efficacy	efficacy	O	O
or	or	O	O
safety	safety	O	O
profile	profile	O	O
of	of	O	O
lovastatin	lovastatin	S_chemical	O
.	.	O	O

CONCLUSION	conclusion	O	O
:	:	O	O
Lovastatin	lovastatin	S_chemical	O
is	is	O	O
highly	highly	O	O
effective	effective	O	O
and	and	O	O
generally	generally	O	O
well	well	O	O
tolerated	tolerated	O	O
as	as	O	O
therapy	therapy	O	O
for	for	O	O
primary	primary	O	O
hypercholesterolemia	hypercholesterolemia	O	S_disease
in	in	O	O
women	women	O	O
.	.	O	O

